Literature DB >> 11782352

Development of spontaneous uterine tumors in low molecular mass polypeptide-2 knockout mice.

Takuma Hayashi1, Denise L Faustman.   

Abstract

The presentation of antigenic peptides by MHC class I molecules is important for tumor rejection by CTLs. Such antigenic peptides are generated as a result of the degradation of intracellular proteins by the proteasome pathway, a process that is influenced by the IFN-gamma-inducible low molecular mass polypeptide-2 (LMP2) subunit of the proteasome complex. LMP2 knockout mice thus exhibit a defect in proteasome function. Female LMP2(-/-) mice are now shown to develop uterine neoplasms, with a disease prevalence of approximately 36% by 12 months of age. This observation indicates that proteasome function is essential for MHC class I-mediated tumor rejection by CTLs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11782352

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

1.  Revisiting the role of the immunoproteasome in the activation of the canonical NF-κB pathway.

Authors:  Eun Ryoung Jang; Na-Ra Lee; Songhee Han; Ying Wu; Lalit Kumar Sharma; Kimberly Cornish Carmony; James Marks; Do-Min Lee; Jung-Ok Ban; Marie Wehenkel; Jin Tae Hong; Kyung Bo Kim; Wooin Lee
Journal:  Mol Biosyst       Date:  2012-06-22

Review 2.  Mice-lacking LMP2, immuno-proteasome subunit, as an animal model of spontaneous uterine leiomyosarcoma.

Authors:  Takuma Hayashi; Akiko Horiuchi; Kenji Sano; Nobuyoshi Hiraoka; Yae Kanai; Tanri Shiozawa; Susumu Tonegawa; Ikuo Konishi
Journal:  Protein Cell       Date:  2010-08-28       Impact factor: 14.870

Review 3.  Immune surveillance of tumors.

Authors:  Jeremy B Swann; Mark J Smyth
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 4.  Interferon-gamma and cancer immunoediting.

Authors:  Gavin P Dunn; Hiroaki Ikeda; Allen T Bruce; Catherine Koebel; Ravi Uppaluri; Jack Bui; Ruby Chan; Mark Diamond; J Michael White; Kathleen C F Sheehan; Robert D Schreiber
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

5.  Therapeutic Potential of Immunoproteasome Inhibition in Duchenne Muscular Dystrophy.

Authors:  Andrea Farini; Clementina Sitzia; Barbara Cassani; Letizia Cassinelli; Rosita Rigoni; Federica Colleoni; Nicola Fusco; Stefano Gatti; Pamela Bella; Chiara Villa; Filomena Napolitano; Rita Maiavacca; Silvano Bosari; Anna Villa; Yvan Torrente
Journal:  Mol Ther       Date:  2016-08-10       Impact factor: 11.454

6.  Biological characterization of soft tissue sarcomas.

Authors:  Takuma Hayashi; Akiko Horiuchi; Kenji Sano; Yae Kanai; Nobuo Yaegashi; Hiroyuki Aburatani; Ikuo Konishi
Journal:  Ann Transl Med       Date:  2015-12

Review 7.  Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?

Authors:  Wout De Wispelaere; Daniela Annibali; Sandra Tuyaerts; Diether Lambrechts; Frédéric Amant
Journal:  Cancers (Basel)       Date:  2021-04-23       Impact factor: 6.639

8.  Molecular Approach to Uterine Leiomyosarcoma: LMP2-Deficient Mice as an Animal Model of Spontaneous Uterine Leiomyosarcoma.

Authors:  Takuma Hayashi; Akiko Horiuchi; Kenji Sano; Nobuyoshi Hiraoka; Yae Kanai; Tanri Shiozawa; Susumu Tonegawa; Ikuo Konishi
Journal:  Sarcoma       Date:  2011-03-08

9.  Molecular mechanisms of uterine leiomyosarcomas: involvement of defect in LMP2 expression.

Authors:  Takuma Hayashi; Yuto Shimamura; Taro Saegusa; Akiko Horiuchi; Yukihiro Kobayashi; Nobuyoshi Hiraoka; Yae Kanai; Hiroyuki Aburatani; Kenji Sano; Ikuo Konishi
Journal:  Gene Regul Syst Bio       Date:  2008-07-22

10.  Mouse models of sarcomas: critical tools in our understanding of the pathobiology.

Authors:  Sean M Post
Journal:  Clin Sarcoma Res       Date:  2012-10-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.